Kallner G, Vitols S, Ljunggren J G
Department of Medicine, Södersjukhuset, Stockholm, Sweden.
J Intern Med. 1996 Jun;239(6):525-9. doi: 10.1046/j.1365-2796.1996.489827000.x.
To obtain a simple standard regimen, suitable for general practice, and based upon the addition of antithyroid drug plus thyroxine for attaining euthyroidism in patients with Graves' disease.
Prospective, randomized trial of patients with Graves' disease followed for 3 months after the initiation of therapy with an antithyroid drug and combined with the later addition of triiodothyronine to keep the patient euthyroid. The patients were randomized, according to birth date, between methimazole and propylthiouracil. Three dose schemes were tested for each antithyroid drug.
The study was performed at the thyroid outpatient units of two general hospitals, with the patients having been referred from primary care.
Ninety-four patients with Graves' disease who were suitable for treatment with antithyroid drugs.
The patients were allocated into six groups. Three groups received methimazole (10 mg every 6th, 8th or 12th h) and three received propylthiouracil (100 mg every 6th, 8th or 12th h). Twenty micrograms of triiodothyronine was added when the patients were euthyroid to avoid hypothyroidism.
The lowest serum free thyroxine level within 3 months of the initiation of the antithyroid treatment.
Fourteen per cent of the patients on methimazole 10 mg every 12th h and 29% on propylthiouracil 100 mg every 12th h did not achieve euthyroidism within the 3-month observation period. All but one patient on methimazole 10 mg every 8th h or propylthiouracil 100 mg every 8th h reduced the free serum thyroxine levels to the normal or hypothyroid range within the observation period. All of the patients on methimazole 10 mg every 6th h and 56% on propylthiouracil 100 mg every 6th h reduced the serum T4 values into the hypothyroid range within the period.
A standard regimen, based upon the addition of methimazole 10 mg every 8th or 6th h or propylthiouracil 100 mg every 8th or 6th h and followed by the addition of thyroxine or triiodothyronine when euthyroid to avoid hypothyroidism, seems to be suitable for attaining euthyroidism within 3 months in patients with Graves' disease. A dose scheme based on methimazole 10 mg every 12th h or propylthiouracil 100 mg every 12th h were found to be unsuitable due to an unacceptably high incidence of failure to attain euthyroidism or hypothyroidism within 3 months.
获得一种简单的标准治疗方案,适用于全科医疗,该方案基于加用抗甲状腺药物和甲状腺素,以使格雷夫斯病患者达到甲状腺功能正常状态。
对格雷夫斯病患者进行前瞻性随机试验,在开始使用抗甲状腺药物治疗后随访3个月,并在之后加用三碘甲状腺原氨酸以维持患者甲状腺功能正常。根据出生日期将患者随机分为甲巯咪唑组和丙硫氧嘧啶组。对每种抗甲状腺药物测试三种剂量方案。
研究在两家综合医院的甲状腺门诊进行,患者由初级医疗转诊而来。
94例适合用抗甲状腺药物治疗的格雷夫斯病患者。
患者被分为六组。三组接受甲巯咪唑(每6、8或12小时10毫克),三组接受丙硫氧嘧啶(每6、8或12小时100毫克)。当患者甲状腺功能正常时加用20微克三碘甲状腺原氨酸以避免甲状腺功能减退。
抗甲状腺治疗开始后3个月内的最低血清游离甲状腺素水平。
每12小时服用10毫克甲巯咪唑的患者中有14%以及每12小时服用100毫克丙硫氧嘧啶的患者中有29%在3个月观察期内未达到甲状腺功能正常状态。每8小时服用10毫克甲巯咪唑或每8小时服用100毫克丙硫氧嘧啶的患者中,除1例患者外,其余患者在观察期内均将血清游离甲状腺素水平降至正常或甲状腺功能减退范围。每6小时服用10毫克甲巯咪唑的所有患者以及每6小时服用100毫克丙硫氧嘧啶的患者中有56%在该期间内将血清T4值降至甲状腺功能减退范围。
一种标准治疗方案,即每8或6小时加用10毫克甲巯咪唑或每8或6小时加用100毫克丙硫氧嘧啶,然后在甲状腺功能正常时加用甲状腺素或三碘甲状腺原氨酸以避免甲状腺功能减退,似乎适合使格雷夫斯病患者在3个月内达到甲状腺功能正常状态。发现每12小时服用10毫克甲巯咪唑或每12小时服用100毫克丙硫氧嘧啶的剂量方案不合适,因为在3个月内未能达到甲状腺功能正常或出现甲状腺功能减退的发生率高得令人无法接受。